Drug Combination Details
| General Information of the Combination (ID: C70450) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Irinotecan Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Phase 1 | [1] | ||
|
Colon cancer
[ICD-11: 2B90]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Biological
Regulation |
Up-regulation | Endoplasmic reticulum stress | ||||
| Induction | ROS generation | |||||
| In-vitro Model | LoVo | CVCL_0399 | Colon adenocarcinoma | Homo sapiens | ||
| HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Curcumin enhances the effects of irinotecan on colorectal cancer cells through the generation of reactive oxygen species and activation of the endoplasmic reticulum stress pathway. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CD24 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CD44 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | EPCAM | Molecule Info | |||
| Down-regulation | Expression | PROM1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | LoVo | CVCL_0399 | Colon adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells. | |||||
